Mirati Therapeutics | MRTX - Заемный капитал



Заемный капитал Изменить Дата
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
Amgen USD 50B 2.43B 2025-12
Astellas Pharma JPY 320B 0 2026-03
AstraZeneca USD 26.14B 19.58B 2025-12
Bayer EUR 31.83B 877M 2025-12
BioCryst Pharmaceuticals USD 428.67M 234.31M 2025-12
Bristol-Myers Squibb USD 42.85B 1.62B 2025-12
Eisai JPY 134.77B 12M 2025-12
Eli Lilly USD 40.87B 5.6M 2025-12
Gilead Sciences USD 22.13B 6M 2025-12
GlaxoSmithKline GBP 14.71B 186M 2025-12
Incyte USD 30.2M 5.17M 2025-12
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
J&J USD 37.53B 1.91B 2026-03
Merck USD 39.97B 6B 2025-09
Moderna USD 610M 584M 2025-12
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Novartis USD 29.59B 5.35B 2025-12
Pfizer USD 57.41B 93M 2025-09
Puma Biotechnology USD 10.87M 222K 2025-06
Roche Holding CHF 27.43B 966M 2025-12
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
Takeda JPY 4.27T 81.29B 2025-12
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09